ECE2017 Eposter Presentations: Thyroid Thyroid (non-cancer) (260 abstracts)
The impact of post-radioiodine therapy SPECT/CT on risk stratification in differentiated thyroid cancer; a bi-institutional study
Szabina Szujo 1 , Livia Sira 2 , Laszlo Bajnok 1 , Beata Bodis 1 , Ferenc Gyory 5 , Orsolya Nemes 1 , Karoly Rucz 1 , Peter Kenyeres 1 , Zsuzsanna Valkusz 6 , Krisztian Sepp 6 , Erzsebet Schmidt 3 , Zsuzsanna Szabo 3 , Sarolta Szekeres 3 , Katalin Zambo 3 , Sandor Barna 4 , Endre V Nagy 2 & Emese Mezosi 1
1Ist Department of Medicine, University of Pecs, Pecs, Hungary; 2Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; 3Department of Nuclear Medicine, University of Pecs, Pecs, Hungary; 4Department of Nuclear Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; 5Department of Surgery, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; 6Ist Department of Medicine, University of Szeged, Szeged, Hungary.
Objective: SPECT/CT has numerous advantages over planar and traditional SPECT images. The aim of this study was to evaluate the role of post-radioiodine therapy SPECT/CT of patients with differentiated thyroid cancer (DTC) in early risk classification and in prediction of late prognosis.
Patients and Methods: 323 consecutive patients, 181 at the University of Pecs and 142 at the University of Debrecen, were investigated after their first radioiodine treatment (1100–3700 MBq). Both SPECT/CT and planar camera images of the head, neck, chest and abdomen regions were taken four days after radioiodine therapy. Patients were re-evaluated 9–12 months later as well as at the end of follow-up (median 37 months).
Results: Post-radioiodine therapy SPECT/CT showed metastases in 22% of patients. Lymph node, lung and bone metastases were detected in 61, 13 and 5 patients, respectively, resulting in early reclassification of 115 cases (36%). No evidence of disease was found in 251 cases at 9-12 months after radioiodine treatment and 269 patients at the end of follow-up. To predict residual disease at the end of follow-up, the sensitivities, specificities and diagnostic accuracies of the current risk classification systems and SPECT/CT were: ATA: 77%, 47% and 53%; ETA: 70, 62 and 64%; SPECT/CT: 61, 88 and 83%, respectively. There was no difference between cohorts of the two institutions when data were analyzed separately.
Conclusions: Based on our bi-institutional experience, the accuracy of post-radioiodine SPECT/CT outweighs that of the currently used ATA and ETA risk classification systems in the prediction of long-term outcome of DTC.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more